Skip to main content
Retour
Watch Compare

ORAMED PHARMACEUTICALS INC.

Qualité des données : 100%
ORMP
Nasdaq Manufacturing Chemicals
3,50 €
▲ 0,02 € (0,43%)
Cap. Boursière: 141,36 M
Prix
3,50 €
Cap. Boursière
141,36 M
Fourchette du Jour
3,41 € — 3,51 €
Fourchette 52 Semaines
1,98 € — 3,76 €
Volume
60 900
Ouverture 3,45 €
Moyenne 50J / 200J
3,40 €
2,81% above
Moyenne 50J / 200J
2,71 €
29,20% above

Quick Summary

Points Clés

Revenue declined -7,25% annually over 5 years
ROE of 35,80% indicates high profitability
Net margin of 3202,50% shows strong profitability
Negative free cash flow of -9,15 M
P/E of 2,21 — trading at a low valuation
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 56,50%

Croissance

Revenue Growth (5Y)
-7,25%
En dessous de la moyenne du secteur (1,82%)
Revenue (1Y)49,25%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
35,80%
Au-dessus de la moyenne du secteur (-53,41%)
ROIC-6,89%
Net Margin3202,50%
Op. Margin-754,40%

Sécurité

Debt / Equity
N/A
Current Ratio22,24
Interest Coverage-17,69

Valorisation

PE (TTM)
2,21
Au-dessus de la moyenne du secteur (-1,48)
P/B Ratio0,70
EV/EBITDAN/A
Dividend YieldN/A

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Manufacturing (1364 pairs)
Métrique Action Médiane du Secteur
P/E 2,2 -1,5
P/B 0,7 1,6
ROE % 35,8 -53,4
Net Margin % 3202,5 -41,5
Rev Growth 5Y % -7,3 1,8
D/E — 0,3

ETFs Holding This Stock

AVSC logo AVSC Avantis U.S. Small Cap Equity ETF
0,00% weight
AVUS logo AVUS Avantis U.S. Equity ETF
0,00% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) 49,25% Revenue Growth (3Y) 22,17%
Earnings Growth (1Y) N/A Earnings Growth (3Y) 240,48%
Revenue Growth (5Y) -7,25% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 2,00 M Net Income (TTM) 64,05 M
ROE 35,80% ROA 33,52%
Gross Margin 0,65% Operating Margin -754,40%
Net Margin 3202,50% Free Cash Flow (TTM) -9,15 M
ROIC -6,89% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 22,24
Interest Coverage -17,69 Asset Turnover 0,01
Working Capital 130,00 M Tangible Book Value 203,28 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio 2,21 Forward P/E N/A
P/B Ratio 0,70 P/S Ratio 70,68
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -6,48%
Market Cap 141,36 M Enterprise Value 89,18 M
Per Share
EPS (Diluted TTM) 1,50 Revenue / Share 0,05
FCF / Share -0,23 OCF / Share -0,23
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 0,45% FCF Conversion -14,29%
SBC-Adj. FCF -13,16 M Growth Momentum 56,50

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 2,00 M 1,34 M 1,34 M 2,70 M 2,70 M
Net Income 64,05 M -19,10 M 5,53 M -37,76 M -22,99 M
EPS (Diluted) 1,50 -0,48 0,14 0,94 —
Gross Profit 13 000,0 — — — —
Operating Income -15,09 M -12,78 M -15,77 M -40,60 M -24,22 M
EBITDA — — — — —
R&D Expenses 6,38 M 6,32 M 8,97 M 27,64 M 20,99 M
SG&A Expenses — — — — —
D&A — — — — —
Interest Expense 853 000,0 2,59 M 2,04 M — —
Income Tax 11,31 M 3,18 M 100 000,0 100 000,0 —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 230,86 M 155,28 M 220,55 M 161,64 M 128,00 M
Total Liabilities — — — — —
Shareholders' Equity 199,74 M 146,27 M 163,82 M 151,81 M 115,77 M
Total Debt 99,55 M 51,01 M 51,01 M 25 000,0 —
Cash & Equivalents 45,95 M — 9,06 M — 77,25 M
Current Assets 133,27 M 143,22 M 162,58 M 157,11 M 95,34 M
Current Liabilities 19,09 M 5,69 M 53,21 M 5,75 M 6,68 M